Treatment options for patients with NSCLC are evolving fast with selective cMet inhibitors and Trk inhibitors now extending the arsenal of personalized therapeutics. Here is a very good synopsis (albeit 2 years old) of NSCLC facts: @Nature @DrRoyHerbstYale
So far, Altmetric has seen
191 X posts from 171 X users, with an upper bound of 1,007,700 followers.
14,180 followers
10,370 followers
@EADavidMD https://t.co/oRwSL1SMbw #lcsm We missed you!
553 followers
RT @HartungIngo: NSCLC therapies are evolving: A recent review summarizes current treatment options: @nature https://t.co/UJ7Sft9qzA. And a…
14,180 followers
NSCLC therapies are evolving: A recent review summarizes current treatment options: @nature https://t.co/UJ7Sft9qzA. And a new study by @NovartisCancer identifies SHP2 inhibition as a strategy to overcome resistance to ALK inhibitors: @NatureMedicine https